Applied Therapeutics' New Drug Application for a rare metabolic disease was rejected by the Food and Drug Administration, ...

Applied Therapeutics' stock plummeted 75 percent after the Food and Drug Administration (FDA) rejected approving govorestat ...

There is more to the comparison, and in the sections below, we discuss why we think BMY will outperform JNJ in the next three ...

PTC Therapeutics faces significant risks with its key revenue sources, Translarna and Emflaza. Find out why I am sticking ...

Amgen Inc.’s stock closed down 4.8% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide ...

Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the ...

The pharmaceutical company's MariTide treatment performed well in a Phase 2 study but not as well as Wall Street expected.

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over one year for patients who were obese or overweight without diabetes. In ...

"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

Oregon will continue keeping an emergency supply of a medication used for abortion under an agreement between the Oregon ...

Following the disappointing results, Cassava stated it would halt a second late-stage trial of simufilam, as well as its open ...